Zobrazeno 1 - 10
of 1 670
pro vyhledávání: '"sodium glucose co-transporter 2"'
Autor:
Kiyoka Matsumoto, Fumiya Goto, Mika Maezawa, Satoshi Nakao, Koumi Miyasaka, Sakiko Hirofuji, Kohei Shiota, Nanaka Ichihara, Moe Yamashita, Yuka Nokura, Tomofumi Yamazaki, Kana Sugishita, Hideyuki Tanaka, Hirofumi Tamaki, Motoyuki Ishiguro, Kazuhiro Iguchi, Mitsuhiro Nakamura
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-7 (2024)
Abstract Sodium-glucose co-transporter 2 (SGLT2) inhibitors are a class of drugs used in the clinical management of patients with type 2 diabetes, and their prescriptions have been increasing in recent years. Herein, we performed a retrospective anal
Externí odkaz:
https://doaj.org/article/433a8437b97d461c9846bd2b672f3102
Autor:
Sunagawa K, Hirai K, Sunagawa S, Kamiya N, Komesu I, Sunagawa Y, Sunagawa H, Nakachi K, Hirai A, Ookawara S, Morishita Y
Publikováno v:
Diabetes, Metabolic Syndrome and Obesity, Vol Volume 17, Pp 3767-3781 (2024)
Kae Sunagawa,1,2 Keiji Hirai,3 Sumito Sunagawa,1,2 Norifumi Kamiya,1 Isao Komesu,1 Yusako Sunagawa,1 Hiroshi Sunagawa,1 Ken Nakachi,4 Aizan Hirai,5 Susumu Ookawara,3 Yoshiyuki Morishita3 1Sunagawa Medical Clinic, Okinawa, Japan; 2Division of Endocrin
Externí odkaz:
https://doaj.org/article/310c83a1ef4f4dd4a7012a977f9d4501
Autor:
Masahiro Isogawa, Hisashi Makino, Cheol Son, Kunihiro Nishimura, Takumi Hirata, Shu Kasama, Yoshihiro Miyamoto, Michio Noguchi, Masato Kasahara, Kiminori Hosoda
Publikováno v:
BMC Endocrine Disorders, Vol 24, Iss 1, Pp 1-8 (2024)
Abstract Background While the Sodium-glucose co-transporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP4) are widely used for the glycemic control in type 2 diabetes mellitus, the differences in the effects of SGLT2 inhibitors and DPP4 inhib
Externí odkaz:
https://doaj.org/article/3c30aa10af6145a49ad751da66897f47
Autor:
Jonathan J.H. Bray, Marco Coronelli, Sam G.C. Scott, John A. Henry, Liam S. Couch, Mahmood Ahmad, Julian Ormerod, James Gamble, Timothy R. Betts, Andrew Lewis, Oliver J. Rider, Peregrine G. Green, Neil Herring
Publikováno v:
ESC Heart Failure, Vol 11, Iss 4, Pp 2314-2322 (2024)
Abstract Aims The trials upon which recommendations for the use of cardiac resynchronization therapy (CRT) in heart failure used optimal medical therapy (OMT) before sodium‐glucose co‐transporter 2 inhibitors (SGLT2i). Moreover, the SGLT2i heart
Externí odkaz:
https://doaj.org/article/9c3575e11de544a78cbdd4429daf1d6d
Publikováno v:
Indian Heart Journal, Vol 76, Iss 4, Pp 229-239 (2024)
Novel therapies for heart failure with reduced ejection fraction (HFrEF) are angiotensin receptor-neprilysin inhibitor (ARNI), sodium-glucose co-transporter 2 inhibitor (SGLT2i), etc. The purpose of this review is to determine the effects of ARNI and
Externí odkaz:
https://doaj.org/article/2d882cf8746c4bb6be1524357dc77b6b
Publikováno v:
BMC Cardiovascular Disorders, Vol 24, Iss 1, Pp 1-9 (2024)
Abstract Background and Aims Sodium-glucose co-transporter 2 (SGLT2) inhibitors have beneficial effects in heart failure (HF), including reverse remodelling, but the mechanisms by which these benefits are conferred are unclear. Inflammation is implic
Externí odkaz:
https://doaj.org/article/33a82ecb2bdf4a93a0f66ac54313e311
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 11 (2024)
The main goals of the pharmacological treatment of Heart failure with reduced ejection fraction (HFrEF) are the reduction of mortality and the prevention of hospitalizations. However, other outcomes such as improvements in cardiac remodeling and clin
Externí odkaz:
https://doaj.org/article/62625629354f45768f73e319bc5fd383
Autor:
Yoichiro Kato, Shuhei Ishii, Yuta Goto, Yasushi Nozaki, Tatsuya Kawamura, Gota Morino, Shintaro Hoshi, Gaku Takahashi, Wataru Obara
Publikováno v:
Clinical Case Reports, Vol 12, Iss 8, Pp n/a-n/a (2024)
Key Clinical Message This is the first case report in which computed tomography (CT) images of a patient with emphysematous pyelonephritis (EPN) capture the time course of emphysema from onset to resolution through conservative treatment. To re‐eva
Externí odkaz:
https://doaj.org/article/d4306fdd168247a285843ff1873b1062
Autor:
Ansari, Huzaifa Ul Haq a, Samad, Muhammad Ammar a, Mahboob, Eman a, Zulfiqar, Eeshal a, Qazi, Shurjeel Uddin a, Ahsan, Areeba b, Ahmed, Mushood c, Ahmed, Faizan d, Ahmed, Raheel e, f, ⁎, Ali, Shafaqat g, Alam, Mahboob h, Rana, Jamal S. i, j, Fonarow, Gregg C. k
Publikováno v:
In American Journal of Preventive Cardiology March 2025 21
Autor:
Peeyush Jain, Santanu Guha, Soumitra Kumar, J. P. S. Sawhney, Kamal Sharma, K. P. Sureshkumar, Ashwani Mehta, Rajnish Dhediya, Kumar Gaurav, Rajan Mittal, Bhavesh Kotak
Publikováno v:
Cardiology and Therapy, Vol 13, Iss 2, Pp 243-266 (2024)
Abstract Heart failure poses a global health challenge affecting millions of individuals, and access to guideline-directed medical therapy is often limited. This limitation is frequently attributed to factors such as drug availability, slow adoption,
Externí odkaz:
https://doaj.org/article/2223a6a2bb8b41fcb4c55ed967232ee6